| Health-Care IT Providers Plan $1.3 Billion Merger Health-care IT providers AllscriptsMisys Healthcare Solutions and Eclipsys agreed to merge in an all-stock deal valued at about $1.3 billion. online.wsj.com |
New York Hospitals Extend Hours As demand has increased, several hospitals in New York are offering outpatient hospital care late into the night or on Saturdays to alleviate weekday crowding. online.wsj.com |
China Nuokang Bio-Pharmaceutical Inc. Appoints Huining Cao to Board of Directors (GlobeNewswire) BEIJING -- China Nuokang Bio-Pharmaceutical Inc. , a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that Mr. us.rd.yahoo.com |
Genmab Recalibrates: Strategic Partnerships, Cost-Cutting The Burrill Report submits: By Michael FitzhughGenmab’s (GNMSF.PK) new CEO, Jan G.J. van de Winkel, is looking to reshape the Danish biotech’s strategy with an emphasis on further cost-cutting and new partnerships. A new research collaboration with Seattle Genetics (SGEN) will give Genmab access to technology to support the development of an early-stage cancer drug, while a renegotiation of its long-running partnership with GlaxoSmithKline (GSK) has boosted Genmab’s financial security and reduced funding concerns for years, says van de Winkel. Complete Story » seekingalpha.com |
Drug Development Spotlight: The mTOR's New Clothes? Michael Becker submits:In 1837, Hans Christian Andersen authored a short tale titled The Emperor’s New Clothes. The main character, so enamored by his appearance and his clothing that he had a different suit for every hour of the day, was swindled by a pair of weavers purporting that they could create clothing from a magical fabric that would only be visible to those who were completely pure in heart and spirit. However, when the Emperor parades before his subjects in the new outfit, a child cries out “But he isn’t wearing anything at all!” The Emperor had no clothes. The tale seems fitting to illustrate the evolution of drugs that target the phosphatidylinositol 3-kinase [PI3K] pathway [see Table 2 for a listing of compounds in clinical development]. Despite ample evidence that pan-PI3K inhibitors and dual PI3K/mTOR inhibitors might offer a therapeutic advantage, tailors continue to weave new compounds targeting individual components of the pathway with presumably superior properties. But does the “mTOR” really have new clothes?Complete Story » seekingalpha.com |